Results 251 to 258 of about 28,388 (258)

Dipeptidyl peptidase‐4 inhibitors: Multitarget drugs, not only antidiabetes drugs (D ipeptidyl peptidase ‐4抑制剂：多靶点药物，不仅仅是降糖药)

Journal of Diabetes, 2014
Chunlan Zhang
exaly  

Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and Lower Extremity Amputation Risk in Diabetic Patients

American Journal of Medicine, 2017
Chun-Chin Chang, Hsin-Bang Leu, Yung-Tai Chen   +2 more
exaly  

Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes

Expert Opinion on Therapeutic Patents, 2003
Koen Augustyns, Pieter Van der Veken, Achiel Haemers   +2 more
exaly  

The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study

Diabetes Research and Clinical Practice, 2018
John-Michael Gamble, , William Midodzi
exaly  

Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database

Diabetes Care, 2018
Jun Shirakawa, Yasuo Terauchi, Shirakawa Jun   +2 more
exaly  

Synthesis of a Dipeptidyl Peptidase-4 Inhibitor

Synfacts, 2014
openaire   +1 more source

Dipeptidyl peptidase-4 (DPP-4) inhibitors

British Journal of Cardiology, 2017
openaire   +1 more source

Dipeptidyl Peptidase 4 Inhibitor–Associated Bullous Pemphigoid

Mayo Clinic Proceedings
Shohei Kitayama, Teruhiko Makino, Tadamichi Shimizu   +2 more
openaire   +2 more sources